A phase II study of sorafenib and metformin in patients with locally advanced and/or metastatic non-smal cell lung cancer (NSCLC) with a K-Ras mutation

Trial Profile

A phase II study of sorafenib and metformin in patients with locally advanced and/or metastatic non-smal cell lung cancer (NSCLC) with a K-Ras mutation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Metformin; Sorafenib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Oct 2013 Interim results (n=55) presented at the 15th World Conference on Lung Cancer
    • 16 May 2012 Planned End Date changed to 2 May 2013.
    • 16 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top